1st Quarter - Report

340B HEALTH for 340B HEALTH

Firm
Client
Income
—
Expenses
$363,453
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

The 340B Drug Pricing Program; FY 2021 L-HHS Appropriations; H.R. 3, Lower Drug Costs Now Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019; H.R. 5281, Drug Price Transparency in Medicaid Act of 2019; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; H.R.6201, Families First Coronavirus Response Act; H.R.748, CARES Act; HR 19, Lower Costs, More Cures Act of 2019

LobbyistCovered position, as disclosed
ELISE CRANSTON —
KATHRYN DIBITETTO —
GREG DOGGETT —
KATE ILAHI Legislative Assistant, Congressman Charlie Melancon (D-LA)
AMANDA SELLERS SMITH —
MAUREEN TESTONI —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Health Resources & Services Administration (HRSA); SENATE

Bills named: H.R. 748 (116th), H.R. 6201 (116th), H.R. 19 (116th), H.R. 6074 (116th), S. 2543 (116th), H.R. 5281 (116th), H.R. 3 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.